Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Devi, Kanta, Shaikh, Muhammad Usman, Ali, Natasha Bahadur, Adil, Salman Naseem, Khan, Maria, Soomar, Salman Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648798/
https://www.ncbi.nlm.nih.gov/pubmed/34926144
http://dx.doi.org/10.1016/j.lrr.2021.100284
_version_ 1784610886849134592
author Devi, Kanta
Shaikh, Muhammad Usman
Ali, Natasha Bahadur
Adil, Salman Naseem
Khan, Maria
Soomar, Salman Muhammad
author_facet Devi, Kanta
Shaikh, Muhammad Usman
Ali, Natasha Bahadur
Adil, Salman Naseem
Khan, Maria
Soomar, Salman Muhammad
author_sort Devi, Kanta
collection PubMed
description In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar.
format Online
Article
Text
id pubmed-8648798
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86487982021-12-17 Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience. Devi, Kanta Shaikh, Muhammad Usman Ali, Natasha Bahadur Adil, Salman Naseem Khan, Maria Soomar, Salman Muhammad Leuk Res Rep Article In Pakistan 76.4% of all NHLs to be diagnosed as DLBCLs. The survival of R-CHOP is better compared to the DA-REPOCH treatment regimen. A prospective follow-up study was conducted with 113 patients to study the outcomes of treatment. Multivariable cox-proportional hazard model was used to estimate the hazard ratios in patients receiving these treatment regimens considering p-value ≤0.05 significant. The survival rate among double/triple expressor lymphoma patients received R-DA-EPOCH was 82.8%, and 83.3% received R-CHOP. For double/triple expressor lymphoma patients received R-DA-EPOCH. The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar. Elsevier 2021-11-29 /pmc/articles/PMC8648798/ /pubmed/34926144 http://dx.doi.org/10.1016/j.lrr.2021.100284 Text en © 2021 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Devi, Kanta
Shaikh, Muhammad Usman
Ali, Natasha Bahadur
Adil, Salman Naseem
Khan, Maria
Soomar, Salman Muhammad
Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
title Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
title_full Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
title_fullStr Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
title_full_unstemmed Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
title_short Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
title_sort outcomes of patients with double/triple expressor diffuse large b-cell lymphoma (dlbcl) treated with r-da-epoch/r-chop: a single-center experience.
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648798/
https://www.ncbi.nlm.nih.gov/pubmed/34926144
http://dx.doi.org/10.1016/j.lrr.2021.100284
work_keys_str_mv AT devikanta outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience
AT shaikhmuhammadusman outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience
AT alinatashabahadur outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience
AT adilsalmannaseem outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience
AT khanmaria outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience
AT soomarsalmanmuhammad outcomesofpatientswithdoubletripleexpressordiffuselargebcelllymphomadlbcltreatedwithrdaepochrchopasinglecenterexperience

Ejemplares similares